Table 1.
Characteirsitcs of included trials.
| Study | Country | Study design | Study group | No. of patients | Age, mean ± SD | Sex, male | Diabetes | Hypertension | CAD | LVEF, mean ± SD |
|---|---|---|---|---|---|---|---|---|---|---|
| Abdulrahman et al. 2021 | Bahrain | Retrospective study | With AF | 30 | 70.0 ± 11.8 | 30 (100%) | 14 (46.7%) | 17 (56.7%) | 10 (33.3%) | 48.6 ± 11.7 |
| Without AF | 462 | 52.3 ± 15.7 | 462 (100%) | 166 (35.9%) | 181 (39.2%) | 49 (10.6%) | 51.2 ± 12.3 | |||
| Denegri et al. 2021 | Italy | Retrospective study | With AF | 30 | 78.5 ± 12.6 | 18 (60.0%) | 10 (33.3%) | 26 (86.7%) | 14 (46.7%) | NS |
| Without AF | 171 | 66.8 ± 14.4 | 111 (64.9%) | 27 (15.9%) | 88 (51.2%) | 21 (12.4%) | NS | |||
| Ergün et al. 2021 | Turkey | Retrospective study | With AF | 37 | 78.4 ± 3.6 | 29 (78.4%) | 14 (37.8% | 31 (83.8%) | 11 (29.7%) | NS |
| Without AF | 211 | 69.5 ± 3 | 147 (69.7%) | 77 (36.5%) | 144 (68.2%) | 54 (25.6%) | NS | |||
| García-Granja et al. 2021 | Spain | Retrospective study | With AF | 54 | 81.6 ± 8.7 | 35 (64.8%) | 13 (24.1%) | 40 (74.1%) | NS | 58.1 ± 11.7 |
| Without AF | 463 | 66.5 ± 14.9 | 255 (55.1%) | 78 (16.4%) | 219 (47.3%) | NS | 62.6 ± 6.9 | |||
| Harrison et al. 2020 | UK | Retrospective study | With AF | 6,589 | 73.6 ± 10.9 | 3,587 (54.4%) | 2692 (40.9%) | 5101 (77.4%) | 3038 (46.1%) | NS |
| Without AF | 6,589 | 73.3 ± 10.9 | 3,611 (54.8%) | 2746 (41.7%) | 5223 (79.3%) | 3062 (46.5%) | NS | |||
| Iacopino et al. 2020 | Italy | Retrospective study | With AF | 12 | 75.9 ± 8.8 | 10 (83.3%) | 5 (41.7%) | 12 (100.0%) | NS | 52.5 ± 5.8 |
| Without AF | 18 | 74.7 ± 10.2 | 10 (55.6%) | 6 (33.3%) | 14 (77.8%) | NS | 55 ± 2.9 | |||
| Ip et al. 2021 | USA | Multicenter retrospective cohort study | With AF | 60 | 74 | NS | NS | NS | NS | NS |
| Without AF | 111 | 63 | NS | NS | NS | NS | NS | |||
| Kelesoglu et al. 2021 | Turkey | Single-center prospectively study | With AF | 33 | 72.42 ± 6.1 | 16 (48.5%) | 7 (21.2%) | 22 (66.6%) | NS | NS |
| Without AF | 625 | 53.78 ± 13.8 | 356 (57.0%) | 112 (17.9%) | 188 (30.0%) | NS | NS | |||
| Kelesoglu et al. 2021 (B) | Turkey | Single-center prospectively study | With AF | 41 | 61.8 ± 6.1 | 20 (48.8%) | 9 (22.0%) | 19 (46.3%) | 6 (14.6%) | 62.8 ± 1.4 |
| Without AF | 741 | 55.5 ± 3.3 | 418 (56.4%) | 121 (16.3%) | 226 (30.5%) | 107 (14.4%) | 63.3 ± 1.2 | |||
| Lee et al. 2021 | Republic of Korea | Retrospective study | With AF | 130 | 71.9 ± 13.7 | 70 (53.9%) | 46 (35.4%) | 98 (75.4%) | 39 (30.0%) | NS |
| Without AF | 7032 | 47.3 ± 18.5 | 2799 (39.1%) | 962 (13.7%) | 1511 (21.5%) | 232 (3.3%) | NS | |||
| Mountantonakis et al. 2021 | USA | Retrospective study | With AF | 1238 | 73.1 ± 13.5 | 777 (62.8%) | 547 (44.2%) | 925 (74.7%) | 584 (47.2%) | NS |
| Without AF | 1238 | 73.6 ± 13.3 | 774 (62.5%) | 548 (44.3%) | 940 (75.9%) | 593 (47.9%) | NS | |||
| Musikantow et al. 2021 | USA | Retrospective study | With AF | 375 | 76.8 ± 2.8 | 225 (60.0%) | 125 (33.3%) | 208 (55.5%) | 90 (24.0%) | NS |
| Without AF | 3595 | 65 ± 3.7 | 2063(57.4%) | 851 (23.7%) | 1159 (32.2%) | 320 (9.0%) | NS | |||
| Pardo Sanz et al. 2021 | Spain | Retrospective study | With AF | 12 | 75.9 ± 9.6 | 8 (66.7%) | 3 (25.5%) | 9 (75.0%) | NS | NS |
| Without AF | 148 | 64.9 ± 16.3 | 88 (59.5%) | 22 (14.9%) | 66 (44.6%) | NS | NS | |||
| Peltzer et al. 2020 | USA | Retrospective study | With AF | 166 | 74.5 ± 13.0 | 120 (72.3%) | 50 (30.1%) | 114 (68.7%) | 45 (27.1%) | 59.4 ± 2.9 |
| Without AF | 887 | 60.1 ± 17.0 | 536 (60.4%) | 263 (29.7%) | 454 (51.2%) | 112 (12.6%) | 58.3 ± 2.8 | |||
| Rubini-Costa et al. 2021 | Spain | Retrospective study | With AF | 151 | 74.6 ± 11.0 | 82 (54.3%) | 46 (30.5%) | 115 (76.2%) | NS | NS |
| Without AF | 151 | 75.1 ± 12.0 | 51 (53.6%) | 46 (30.5%) | 105 (69.5%) | NS | NS | |||
| Russo et al. 2021 | Italy | Retrospective multicenter study | With AF | 71 | 73.69 ± 9.9 | 46 (64.8%) | 22 (31.0%) | 57 (80.3%) | 21 (29.6%) | NS |
| Without AF | 343 | 65.54 ± 15.48 | 207 (60.3%) | 84 (24.6%) | 206 (60.2%) | 45 (13.2%) | NS | |||
| Slipczuk et al. 2021 | USA | Retrospective study | With AF | 16 | 65.7 ± 4.1 | 12 (75.0%) | 9 (56.3%) | 14 (87.5%) | 8 (50.0%) | NS |
| Without AF | 363 | 67.5 ± 3 | 171 (47.1%) | 218 (60.1%) | 254 (70.0%) | 143 (39.4%) | NS | |||
| Spinoni et al. 2021 | Italy | Retrospective study | With AF | 134 | NS | NS | NS | NS | NS | NS |
| Without AF | 503 | NS | NS | NS | NS | NS | NS | |||
| Urbarri et al. 2021 | Spain | Retrospective study | With AF | 233 | 79.7 ± 9.7 | 134 (57.5%) | 69 (29.6%) | 189 (81.1%) | NS | NS |
| Without AF | 233 | 79.1 ± 11.5 | 134 (57.5%) | 69 (29.6%) | 189 (81.1%) | NS | NS |
AF — atrial fibrilation; CAD — coronary artery disease; LVEF — left ventricular ejection fraction; NS — not specified; SD — standard deviation; UK — United Kingdom; USA — United States of America